Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a buy rating to a hold rating in a research report report published on Thursday.

A number of other research firms have also recently weighed in on JAZZ. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Piper Sandler reissued an “overweight” rating and issued a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Barclays reaffirmed an “overweight” rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $108.98 on Thursday. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $148.06. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 15.35, a PEG ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a 50-day simple moving average of $115.73 and a two-hundred day simple moving average of $122.01.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company’s revenue was down .5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.68 EPS. On average, equities analysts forecast that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Seamus Mulligan acquired 1,621 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the purchase, the director now directly owns 101,621 shares of the company’s stock, valued at $10,466,963. The trade was a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the transaction, the chief executive officer now owns 439,307 shares of the company’s stock, valued at $51,113,369.45. This represents a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock worth $311,699,000 after acquiring an additional 37,108 shares during the period. Dimensional Fund Advisors LP boosted its position in Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after purchasing an additional 293,360 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares during the period. Capital World Investors grew its stake in shares of Jazz Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock worth $236,860,000 after purchasing an additional 104,195 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.